KEGG   DRUG: Onasemnogene abeparvovec
Entry
D11559                      Drug                                   

Name
Onasemnogene abeparvovec (USAN/INN);
Onasemnogene abeparvovec-xioi;
Zolgensma (TN)
Product
Remark
Product: D11559<US>
Efficacy
Spinal muscular atrophy treatment
  Disease
Spinal muscular atrophy (bi-allelic SMN1 mutations) [DS:H00455]
Comment
Gene therapy product
Target
SMN1 [HSA:6606] [KO:K13129]
Brite
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Signaling molecules
   Spliceosome
    SMN1
     D11559  Onasemnogene abeparvovec (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 Cellular and gene therapy products
  D11559
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11559
New drug approvals in Japan [br08318.html]
 Cellular and gene therapy products
  D11559
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11559
Other DBs
CAS: 1922968-73-7
PubChem: 384585535
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system